Development of immediate release Rupatadine fumarate 10 mg tablets: A Quality by Design (QbD) approach

Abstract

Objective: The main objective of this research is to develop an immediate release Rupatadine fumarate 10 mg tablets formulation by direct compression, through a Quality by Design approach in Costa Rica.

Methods: According to a Quality by Design approach; Target Product Profile, Quality Target Product Profile, and the Critical Quality Attributes were defined. In the preformulation study, compatibility tests were carried out between the raw materials. The Critical Material Attributes were established using Quality Risk Management. Three formulation prototypes were prepared by direct compression and its Critical Process Parameters were defined. The analysis of the prototypes was realized in terms of organoleptic properties, identification, potency, content uniformity, dissolution, disintegration, friability and loss by drying.

Results: All the prototypes showed a white or slightly pink surface, potency between 90.0 –110.0 % of the labeling, an acceptance value for the content uniformity lower than the specification (AV < 15), the dissolved amount of active pharmaceutical ingredient was greater than 85.0 % at 30 minutes, friability less than 1.0 %, a disintegration time less than 15 minutes and moisture content less than 2.0 %.

Conclusions: The approaching of a Quality by Design model to the current development allowed to obtain satisfactory results in the three formulation prototypes. The excipients to be used can be lactose monohydrate, microcrystalline cellulose, sodium croscarmellose, pregelatinized starch, magnesium stearate, stearic acid, and PVP K-30.

Keywords:

• Antihistaminic
• direct compression
• formulation
• immediate release
• pharmaceutical research and development
• quality by design
• Rupatadine fumarate
• tablets

Correction Statement

This article has been republished with minor changes. These changes do not impact the academic content of the article.

Acknowledgements

The authors thanks to the Institute of Pharmaceutical Research Pharmacy Faculty, University of Costa Rica. This study was supported by the Institute of Pharmaceutical Research (INIFAR) of the Pharmacy Faculty, University of Costa Rica.

Disclosure statement

No potential conflict of interest was reported by the authors.

Additional information

Funding

This study was supported by the Institute of Pharmaceutical Research (INIFAR) of the Pharmacy Faculty, University of Costa Rica.